Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Atomo Diagnostics Ltd. ( (AU:AT1) ) has provided an announcement.
Atomo Diagnostics Ltd. has announced the issuance of 3,100,000 unquoted equity securities in the form of options expiring on June 30, 2028, with an exercise price of $0.0115. This issuance is part of an employee incentive scheme and is not intended to be quoted on the ASX. The move is likely aimed at motivating and retaining key personnel, potentially impacting the company’s operational efficiency and market competitiveness.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. operates in the medical diagnostics industry, focusing on the development and commercialization of rapid diagnostic test devices. The company is known for its innovative point-of-care testing solutions, which are designed to be user-friendly and accessible, catering primarily to the healthcare sector.
Average Trading Volume: 1,593,324
Technical Sentiment Signal: Buy
Current Market Cap: A$31.6M
See more data about AT1 stock on TipRanks’ Stock Analysis page.